Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average Price Target from Analysts
Mar 14, 2025
Therapies Invest Information
CytoMed Therapeutics Offers Free Cell Banking to Eligible Shareholders for Future Precision Medicine
Mar 18, 2024
Aeglea BioTherapeutics AGLE Receives Sell Rating Amid Market Dynamics
Nov 13, 2023
StockNews.com Issues a Sell Rating for Minerva Neurosciences Amid Institutional Trading Activity
Nov 12, 2023